ロード中...
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
BACKGROUND: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy. However, their use is complicated by immune-related adverse events (irAEs), including endocrine adverse events (eAEs...
保存先:
| 出版年: | Endocr Connect |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Bioscientifica Ltd
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5937198/ https://ncbi.nlm.nih.gov/pubmed/29739808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-18-0079 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|